Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeHistocompatibility TestingGraft SurvivalStem CellsRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineCord Blood Stem Cell TransplantationRemission InductionLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapySiblingsHematopoiesisTime FactorsTransplantation ImmunologySurvival RateCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalMice, Inbred C57BLSevere Combined ImmunodeficiencyFollow-Up StudiesFlow CytometryMultiple MyelomaOpportunistic InfectionsCystitisHematopoietic Stem Cell MobilizationMinor Histocompatibility AntigensAntigens, CD34Leukemic InfiltrationLeukemia, MyeloidImmunosuppressionNeoplasm, ResidualKidney TransplantationAntilymphocyte SerumSalvage TherapyLymphoproliferative DisordersCell DifferentiationBone and BonesGraft RejectionAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusImmunocompromised HostPrognosisBlood Group IncompatibilityFatal OutcomeBronchiolitis ObliteransRisk FactorsBone Marrow PurgingCyclosporineCytarabineMesenchymal Stem Cell TransplantationColony-Forming Units AssayCell TransplantationMelphalanCell LineageMycosesPrimary MyelofibrosisLymphoma, Non-HodgkinRadiation ChimeraGranulocyte Colony-Stimulating FactorCells, Cultured